Enzymatica moves forward its year-end report for 2015
February 03 2016 - 4:07AM
Enzymatica will move forward the
announcement of its year-end report 2015 from February 16 to
February 15, 2016. The reason is that the company prefers to
announce the year-end report the same day as the Extraordinary
General Meeting takes place, that is February 15, on account of
Enzymatica's bid on the Icelandic R&D company Zymetech.
For
more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com
About Enzymatica AB
Enzymatica is a life science company whose business concept is to
offer effective help against some of our most common diseases where
viruses or bacteria play a decisive role. Over a short period the
company has developed a unique oral spray for colds, ColdZyme®, and
launched it on six markets. The product has become one of the
leading articles for colds in Swedish pharmacies. Development
includes medical devices in upper respiratory infections and oral
health, and veterinary products. The company is headquartered in
Lund, Sweden and is listed on Nasdaq First North. For more
information, please visit www.enzymatica.com.
Enzymatica's certified adviser is Erik Penser
Bankaktiebolag.
Press Release (PDF)
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
HUG#1983356
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Enzymotec Ltd. - Ordinary Shares (delisted) (NASDAQ): 0 recent articles
More Enzymatica AB News Articles